A phase I trial of RB-571/RB-515 (REG3) for potential use as an antiplatelet therapy.
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2011
At a glance
- Drugs RB 571/RB 515 (Primary)
- Indications Diabetic complications; Thrombosis
- Focus Adverse reactions
- 07 Nov 2011 Planned initiation date changed to 31 Dec 2011, according to a Regado Biosciences media release.
- 13 Aug 2010 New trial record